KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression

Abstract Cholangiocarcinoma (CCA) is a liver cancer subtype with poor survival rates. KRAS mutations are found in 15–40% of CCA, representing a new potential treatment target. Whether KRAS inhibition leads to CCA tumor regression is unknown, partly due to the lack of conditional animal models. A con...

Cijeli opis

Bibliografski detalji

Glavni autori:	Youwei Qiao, Matthew F. Yee, Chaitanya N. Parikh, Boyang Ma, Yueying Cao, Yu‐Huan Shih, Joae Qiong Wu, Marcus Ruscetti, Shun‐Qing Liang, Wen Xue
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2026-01-01
Serija:	Advanced Science
Teme:	biliary malignancy cholangiocarcinoma KRAS inhibition oncology
Online pristup:	https://doi.org/10.1002/advs.202511312
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!